Health
Beyond weight loss: How did multi-year clinical trials prove GLP-1 therapies cut heart attack and neuro-inflammatory risks?
Comprehensive clinical evidence from the SELECT study demonstrates that GLP-1 receptor agonists reduce major cardiovascular events by 20% independent of glycemic control.
✍️
Bilginet Analiz Masası
Stratejik Dış Politika ve Güvenlik Masası
📅 31.10.2026 16:08
•
⏱️ 1 dk okuma
Bilginet Health Sciences Desk — Originally synthesized for glycemic control in Type 2 diabetes, GLP-1 receptor agonists represent an expansive pharmacological breakthrough in preventative cardiology.
Peer-reviewed multicenter clinical trials confirm significant systemic anti-inflammatory benefits, lowering secondary stroke risks and kidney degeneration across non-diabetic cohorts.
ℹ️ Kaynak & Telif:
Bilginet Analiz Masası
(Orijinal Bağlantı)
— Bilginet Analiz Masası Özel İnceleme Raporu
Haberi Paylaş:
💬 Yorumlar 0
💬
Henüz yorum yapılmamış. İlk yorumu siz yazın!
